Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Valneva SENASDAQ: VALN

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of €15.14M fell 21.8% year over year, ahead of the -23.0% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 8.5% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.

Context

  • Selling, general & admin amounted to 42.8% of revenue in FY2025, down 13.3 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of €61.18M (-18.1%) for the fiscal year ending Dec 2026, a step up from the -21.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
€15.14M-8.5% QoQ
Last fiscal yearDec 2025
€74.68M-21.5% YoY
LTMMar 2026
€70.46M-23.0% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.8%-16.5%+5.3 pp
1 year-21.5%-18.1%+3.4 pp
3-year CAGR+9.1%+9.9%+0.9 pp
5-year CAGR+17.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

EUR · from the income statement

Latest · FY2025
74.68M EUR
Year-over-year change
-21.5%
4-year CAGR
+1.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -23.0% is the 6th highest of 7, against a peer median of +3.2%.
  • Selling, general & admin amounts to 45.1% of revenue for VALN, versus a peer median of 96.1%.
VALN Competitors
Selling, General & Admin for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$16.46B USD+48531.9%-28.7%—
MRNAModerna, Inc.LTM Sep 2026$979M USD-7.7%-3.5%38.8%
IBRXImmunityBio, Inc.LTM Sep 2026$185.41M USD+24.0%+12.7%101.6%
PCVXVaxcyte, Inc.LTM Jun 2026$132.67M USD+14.1%+48.1%—
NVAXNovavax, Inc.LTM Mar 2026$127.98M USD-57.1%-32.5%21.5%
VALNValneva SELTM Mar 2026€70.46M EUR-23.0%+9.1%45.1%
VIRVir Biotechnology, Inc.LTM Mar 2026$69.19M USD——105.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M USD-11.6%+0.0%96.1%
Peer median (excluding VALN) —+3.2%-1.7%96.1%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.